Ionis Pharmaceuticals, Inc. (IONS) Stock
IONS Key Statistics
About Ionis Pharmaceuticals, Inc.
Founded in 1989 and headquartered in Carlsbad, California, Ionis Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery and development of RNA-targeted therapies within the United States. Its commercial portfolio includes three key medications: SPINRAZA, prescribed for spinal muscular atrophy (SMA) in both children and adults; TEGSEDI, an injectable treatment targeting polyneuropathy associated with hereditary transthyretin-mediated amyloidosis in adult patients; and WAYLIVRA, which addresses familial chylomicronemia syndrome and familial partial lipodystrophy. Ionis also maintains a robust pipeline, with several drug candidates currently in Phase 3 clinical trials. These include Eplontersen, a monthly self-administered subcutaneous injection designed for all forms of TTR amyloidosis; Olezarsen, intended for individuals with severe hypertriglyceridemia (SHTG); Donidalorsen, for patients suffering from hereditary angioedema; ION363, aimed at amyotrophic lateral sclerosis (ALS); Pelacarsen, developed for those with established cardiovascular disease and elevated lipoprotein(a); and Tofersen, which works by inhibiting the production of superoxide dismutase 1. Beyond these late-stage assets, the company is actively researching treatments for metabolic, infectious, renal, and ophthalmic diseases, as well as various types of cancer. The firm engages in significant collaborations, notably a strategic partnership with Biogen Inc. Additionally, it holds licensing and collaboration agreements with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc.
CEO: Brett Monia. Company website
IONS — Frequently Asked Questions
What is the IONS stock price today?
Ionis Pharmaceuticals, Inc. (IONS) trades at $44.44, down 4.94% on the day, as of Sep 20, 2026 14:59 UTC.
What is Ionis Pharmaceuticals, Inc.'s market cap?
Ionis Pharmaceuticals, Inc. has a market capitalisation of $7.39B, calculated from the live IONS share price and shares outstanding.
What is the P/E ratio of IONS?
IONS has no meaningful price-to-earnings ratio: Ionis Pharmaceuticals, Inc. lost $3.46 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Ionis Pharmaceuticals, Inc. make?
Ionis Pharmaceuticals, Inc. generated revenue of $873.76M over the trailing twelve months, which puts the stock at 8.45 times sales.
What is the 52-week range for IONS?
IONS has traded between $44.27 and $86.74 over the past 52 weeks, and the last price is 48.8% below that high.
Is Ionis Pharmaceuticals, Inc. profitable?
No. Ionis Pharmaceuticals, Inc. is loss-making, with a net margin of -64.64% over the trailing twelve months.
What is the analyst price target for IONS?
Wall Street analysts rate IONS Buy, with an average price target of $87.00, 95.8% above the current price.
What sector is Ionis Pharmaceuticals, Inc. in?
Ionis Pharmaceuticals, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Ionis Pharmaceuticals, Inc.?
Brett Monia is the chief executive of Ionis Pharmaceuticals, Inc., which employs 1,480 people.
Where can I track IONS in real time?
QFI Terminal shows IONS with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See IONS live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open IONS in Terminal See plans